LIVE INFLUENZA VACCINE FOR CHILDREN AND ADULTS: TRANSMISSIBILITY IN CHILDREN 3-6 YEARS OF AGE


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences, St. Petersburg Live attenuated influenza vaccines (LAIV) are used in Russia to immunize all population groups, including children. The immunogenicity, acceptance, and transmissibility of the components of commercially available trivalent LAIV vaccine in vaccinated children aged 3 to 6 years were studied. Vaccine viruses were isolated from nasal swabs of the vaccinees, using chicken embryos and MDCK cells. The use of a combination of these two culture systems produced the best effect in isolating vaccine viruses. Examination of placebo group children who were in constant contact with the vaccinated subjects showed that LAIV strains had not been transmitted from the vaccinated to unvaccinated children. The acceptance of vaccine virus correlated well with its immunogenicity.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. LARIONOVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: nvlarionova@mail.ru
St. Petersburg

I. KISELEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

E. GRIGORIEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

I. ISAKOVA-SIVAK

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

S. DONINA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

L. RUDENKO

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

Әдебиет тізімі

  1. Александрова Г.И., Климов А.И. Живая вакцина против гриппа. СПб: Наука, 1994.
  2. Klimov A.I., Kiseleva I.V., Desheva J.A. et al. Live attenuated reassortant influenza vaccine prepared usingA/Leningrad/134/17/57 (H2N2) donor strain is genetically stable after replication in children 3-6 years of age In: Proceedings of options for the control of influenza IV. Hersonissos, Crete, Greece. 23-28 September 2000. Amsterdam: Elsever Sciense, 2001: 951-954.
  3. van Voorthuizen F., Jens D., Saes F. Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold adapted A/Ann Arbor/6/60 (H2N2) strains. Antivir. Res. 1981; 1: 107-122.
  4. Vesikari T., Karvonen A., Korhonen T. et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Ped. Inf. Dis. J. 2006; 25 (7): 590-595.
  5. Иванова В.Т., Бурцева Е.И., Слепушкин А.Н. и др. Характеристика штаммов вируса гриппа А(Н3N2) в эпидемическом сезоне 2003-2004 гг. в России. Вопр. вирусол. 2006; 1: 19-23.
  6. Litvinova O., Konovalova N., Lobova T. The etiological surveillance for influenza in Russia during the seasons 1993— 2003. International Congress Series 1263. 2004: 295-298.
  7. Демидова С.А., Гадашевич В.Н., Кириллова Ф.М. и др. Выделение и изучение вирусов гриппа А на разных клеточных культурах. Вопр. вирусол. 1979; 4: 346-350.
  8. Davies H.W., Appleyard G., Cunningham P. et al. The use of a continuous cell line for the isolation of influenza viruses. Bull. WHO 1978; 56: 991-993.
  9. Инструкция по применению вакцины гриппозной аллантоисной интраназальной живой сухой. Утверждена Главным санитарным врачом РФ Г.Г. Онищенко 16 июня 2004 г.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2012

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>